Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk - Wikidata - wikimedia - TriplyDB

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk

http://www.wikidata.org/entity/Q35539305

about

Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension.Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?Interactions between angiotensin AT1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock.

P2860

Q36410269-FAED5029-E388-4628-B77A-583D149A4ECE Q37053287-6BDCFE71-5E93-4738-A033-03E9AC200354 Q37141972-40703276-B403-4770-8A09-64A0EE681008 Q37176172-82CDE126-B085-4517-AD59-AC4623AF9684 Q38050865-20BC348A-EAD6-4790-A2FA-78735DBC4729 Q38144197-0C553294-A143-491B-9214-FB48911BABE4 Q45132932-333D3E33-DF0F-4220-A9CB-ED5631F750F8

P2860

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk

http://www.wikidata.org/entity/Q35539305

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Indications for and utilizatio ...... ts at high cardiovascular risk

@ast

Indications for and utilizatio ...... ts at high cardiovascular risk

@en

type

label

Indications for and utilizatio ...... ts at high cardiovascular risk

@ast

Indications for and utilizatio ...... ts at high cardiovascular risk

@en

prefLabel

Indications for and utilizatio ...... ts at high cardiovascular risk

@ast

Indications for and utilizatio ...... ts at high cardiovascular risk

@en

P1433

Q35539305-0C45A547-0A1E-4851-ADC0-68C0B456B328

P1476

Q35539305-EFC52446-7623-4BDB-B2B8-6CBA01092E7A

P2093

Q35539305-C00FC9A3-B4BD-4B0F-AC79-648E7EF51279

P2860

Q35539305-012004FA-B4BD-4FDC-AB75-55F8C19587AE

Q35539305-025AD22B-D7C0-4EF1-910B-D4738F9F394D

Q35539305-033BCB76-CDB2-42F1-BE12-C89601659716

Q35539305-04F92987-44A0-437D-9D84-6E9B22625338

Q35539305-0721BFA9-2588-4416-B650-8BC82968FD07

Q35539305-07812A2F-783F-41BB-80BF-D58A94781E48

Q35539305-07B9A45E-A171-4190-9E01-94A449950B08

Q35539305-0A944447-406F-4856-B490-72C6B431ADDE

Q35539305-0A96FEA9-3662-4F72-86E7-33EC8499ECD1

Q35539305-0B0D8246-51F6-431A-92A4-174764FA39B4

P304

Q35539305-A82E54FC-93D8-414B-9F2B-3F40273ED969

P31

Q35539305-32ABD4F4-BB46-447D-B5D5-B53BF28532CB

Q35539305-E79D127A-EFFB-486D-B816-91DB42C95BC1

P356

Q35539305-6FD5D611-72E9-4480-B98A-B176E7E8B465

P407

Q35539305-C21B511B-7B63-49B6-BED1-904485DABF02

P478

Q35539305-2B54DFBF-94B7-4D97-BA3C-FADCBC3BDB91

P577

Q35539305-28008C67-21FD-45C3-BA69-4896C1096844

P698

Q35539305-E4A1272E-5954-48B0-9621-7367C8A7B0E6

P921

Q35539305-086A8F8A-5FB6-4E9F-9F18-BE2629850394

Q35539305-3A920C8C-EFD5-4DE9-B5E3-3587430D70CC

Q35539305-6B451BAB-EC86-41A7-B8FE-99E22BB402EF

Q35539305-7B4B7045-0730-4DC8-9215-2E9F6033E9A8

P932

Q35539305-543B285B-B9BF-476E-A35E-9AC312A63C01

P356

P1433

Vascular Health and Risk Management

P1476

Indications for and utilizatio ...... ts at high cardiovascular risk

@en

P2093

Csaba Farsang

http://www.w3.org/2001/XMLSchema#string

P2860

Projections of global mortality and burden of disease from 2002 to 2030

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Angiotensin receptor blockers and myocardial infarction

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients

P304

605-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.S23468

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22102784

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

cardiovascular disease

arterial hypertension

preventive health services

P932

3212426

http://www.w3.org/2001/XMLSchema#string